BDBM102338 US10562854, No. C14::US8536181, C14::US9278930, C14

SMILES CC(NCc1ccn(Cc2ccccc2)c(=O)c1O)c1ccccc1

InChI Key InChIKey=VGDRCKOTQHHWTA-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 102338   

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US8536181, C14 | US9278930, C14 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMAssay Description:EGLN enzyme activity assay is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-TOF MS.More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US8536181, C14 | US9278930, C14 | US10562854, No. ...)
Affinity DataIC50: 2.06E+4nMAssay Description:ELISA assay using VEGF.More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US8536181, C14 | US9278930, C14 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMpH: 7.5Assay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US8536181, C14 | US9278930, C14 | US10562854, No. ...)
Affinity DataIC50: 2.06E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US8536181, C14 | US9278930, C14 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US8536181, C14 | US9278930, C14 | US10562854, No. ...)
Affinity DataIC50: 2.06E+4nMAssay Description:HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetEgl nine homolog 1(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US8536181, C14 | US9278930, C14 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetVascular endothelial growth factor A(Human)
Aerpio Therapeutics

US Patent
LigandPNGBDBM102338(US8536181, C14 | US9278930, C14 | US10562854, No. ...)
Affinity DataIC50: 2.06E+4nMAssay Description:VEGF: HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following ove...More data for this Ligand-Target Pair
In DepthDetails
US Patent